摘要
目的:探讨选择性环氧合酶-2(COX-2)抑制剂塞来昔布(celecoxib)对大鼠实验性Barrett食管发生发展的影响。方法:60只8周龄雄性SD大鼠,50只行食管空肠吻合术2周后随机分为2组。术后4周,塞来昔布组大鼠塞来昔布10 mg/(kg.d-1)经食管灌入;对照组经食管灌入生理盐水1 ml;另外,10只大鼠为假手术组。术后20周处死动物,观察比较3组动物大体组织变化、食管炎、Barrett食管及食管腺癌的发生情况,免疫组织化学检测COX-2的表达,酶联免疫竞争法检测PGE2的水平。结果:术后20周,塞来昔布组轻、中、重度食管炎发生率分别为14/19(73.68%)、4/19(21.05%)、1/19(5.26%);对照组为4/17(23.53%)、5/17(29.41%)、8/17(47.06%),两组比较有显著差异(P<0.05)。Barrett食管发生率塞来昔布组为7/19(36.84%),对照组为13/17(76.47%),两组比较有显著差异(P<0.05)。Barrett食管不典型增生发生率塞来昔布组为2/19(10.53%),对照组为8/17(47.06%),两组比较有显著差异(P<0.05)。COX-2蛋白表达塞来昔布组为1/7(14.29%),对照组为10/13(76.92%),两组比较有显著差异(P<0.05)。塞来昔布组PGE2水平(1480.1±489.8)pg/mg.protein,显著低于对照组(2933.8±862.9)pg/mg.protein(P<0.001)。假手术组组织学未见异常。结论:塞来昔布对大鼠反流性食管炎、Barrett食管和食管腺癌的发生发展有化学预防作用。
Objective： To examine the chemopreventive effect of selective cyclooxygenase-2 （COX-2） inhibitor celeeoxib for Barrettes esophagus in rats. Methods： Fifty 8-week-old male Sprague Dawley rats underwent esophagojejunostomy to induce Barrett＇s esophagus model. Four weeks after operation the animals were given celecoxib 10 mg/（kg·d^-1） （celecoxib group）,or saline 1 ml （control group）. Another 10 rats were sham operation group. All animals were sacrificed at 20 week after surgery. The degree of inflammation, Barrett＇ s esophagus, adenocarcinoma,COX-2 expression and PGE2 of animals were assessed. Results： Among 60 rats, 6 rats died in celecoxib group, 8 rats died in control group, 1 rat died in sham operation group ,and 45（75%） rats completed the study. The incidence of mild,moderate and severe degree esophageal inflammation in celecoxib group and control group was 14/19（73.68%）,4/19（21.05%）,1/19 （5.26%） ;4/17（23.53%） ,5/17 （29.41%）, 8/17（47.06%） （P〈0.05） ,respectively. The incidence of Barrett＇s esophagus was 7/19 （36.84%）,13/17（76.47%） in two group respectively （P 〈 0.05） ;The incidence of Barrett＇s esophagus with dysplasia was 2/19（10.53%）,8/17（47.06%） （P 〈 0.05）, respectively. The expression of COX-2 was 1/7 （14.29%）, 10/13 （76.92 %） （P 〈0.05） in two groups. PGE2 content was significantly lower in the celecoxib group than that in control group （P〈 0. 001）. No esophageal pathological changes were found in sham operation group. Conclusion： Selective COX-2 inhibitors celecoxib can inhibit inflammations,development of Barrett＇s esophagus and esophagus adenocarcinoma.
出处
《浙江大学学报（医学版）》
CAS
CSCD
北大核心
2009年第5期498-504,共7页
Journal of Zhejiang University(Medical Sciences)
